The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlethora Solutions Holdings Plc Regulatory News (PLE)

  • There is currently no data for PLE

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

CEO Appointment

20 Dec 2013 15:34

RNS Number : 1500W
Plethora Solutions Holdings PLC
20 December 2013
 



 

 

20 December 2013

 

Plethora Solutions Holdings PLC

("Plethora" or the "Company")

CEO Appointment

 

 

Plethora Solutions Holdings plc (AIM: PLE) is pleased to announce the appointment of Jamie Gibson, who will join the Board as CEO with effect from 1 January 2014. Mr. Gibson is tasked primarily with driving the Company's commercialisation of PSD502 in Europe, the United States (subject to regulatory approval) and other selected territories. In addition, Mr. Gibson will lead the Company's initiatives on its manufacturing strategy and the extension of the Company's intellectual property platform.

 

Mr. Gibson has spent most of his professional career working with Jim Mellon for over 17 years at Regent Pacific Group Limited ("Regent Pacific") specialising in corporate finance and direct equity investments. Mr Mellon co-founded Regent Pacific and is Co-Chairman. Mr. Gibson has led many successful investments and divestures with values in excess of US$500 million, including significant fund raisings over his career with Regent Pacific. Regent Pacific is a diversified mining group focused, primarily, on the Asian Pacific region.

 

Prior to joining Regent Pacific Group, Mr. Gibson worked at Clifford Chance, Coopers & Lybrand and KPMG. Mr. Gibson has a law degree from Edinburgh University.

 

Jim Mellon Chairman of Plethora said:

 

"We welcome Jamie whom I have worked with at Regent Pacific for over 17 years; we wish him every success in his new role. We are extremely pleased to have such an experienced team lead our business development activities, which is part of the Company's disciplined approach to increasing shareholder value through the successful commercialisation of PSD502."

 

Further information that is required to be disclosed with regards to the appointment of Jamie Gibson pursuant to Schedule 2 paragraph (g) of the AIM Rules is set out below.

 

Jamie Alexander Gibson, aged 47, has or has held within the last five years, the following directorships or partnerships:

 

Current

Past five years

Alphorn Management Limited

Venturex Resources Limited

Amerinvest Coal Industry Holding Company (BVI) Limited

 

BC Iron Limited

Amerinvest Coal Industry Holding Company (Hong Kong) Limited

 

CCEC Sheng Li (Hong Kong) Limited

Amerinvest Coal Industry Holding Company Limited

 

Golden Bridge Investment and Securities Co Limited

Capital Nominees Limited

Cycleteck Investments Limited

Interman Holdings Limited

Regent Coal (BVI) Limited

Interman Limited

 

Regent Coal (HK) Limited

MinMetallurgical Consultants Limited

 

Regent Coal Limited

PT Regent Resources Indonesia

Regent Metals (Jersey) Limited

Regent (Australia) Limited

Regent Metals Limited

Regent Coal (Beijing) Consulting Limited

 

Regent Minerals Limited

Regent Coal (Holdings) Limited

Simao Regent Minerals Limited

Regent Corporate Finance Limited

Venturex Resources Limited

Regent Financial Services Limited

Xinjiang Regent Coal Limited

Regent Fund Management (Asia) Limited

 

Yunnan Simao Shanshui Copper Company Limited

Regent Fund Management Limited

 

Regent (Indonesia I) Limited

Regent (Indonesia II) Limited

Regent Markets Group Limited

Regent Metals Australia Pty Limited

Regent Metals Holdings Limited

Regent Pacific Group (Hong Kong) Limited

 

Regent Pacific Group Limited

Regent Pilbara Pty Limited

Regent Pilbara II Pty Limited (Australia)

RPG (Bahamas) Limited (Bahamas)

RPG Investments I Limited

Mr. Gibson, Regent Pacific and Clara Cheung, a former executive director were criticised by the Stock Exchange of Hong Kong ("HKSE") on 24 November 2010. According to the HKSE, Mr. Gibson, in his capacity as an executive director of Regent Pacific, had failed to use his best endeavours to procure the company's compliance with a rule in relation to a HKSE listed company purchasing its own shares. Regent Pacific had violated the HKSE's rule when it repurchased its own shares at a price of five per cent. or more above the average closing market price for the five proceeding trading days in 2008.

 

Mr. Gibson, Regent Pacific and Clara Cheung co-operated openly and promptly with the HKSE, accepted the sanction imposed, further apologised to shareholders and accepted full responsibility for the breaches.

 

No further disclosures are required under Rule 17 and Schedule 2 paragraph (g) of the AIM Rules for Companies.

 

-Ends-

 

Enquiries:

Plethora Solutions

Mike Wyllie, CSO

Mike Collis, CFO

Tel : +44(0) 20 3077 5400

Daniel Stewart (Nomad & Joint Broker)

David Hart / Ciaran Walsh (Nomad)

Martin Lampshire (Broker)

Tel : +44(0) 20 7776 6550

 

Hybridan LLP (Joint Broker)

Claire Louise Noyce

William Lynne

 

Tel: +44(0) 20 7947 4350

Tel: +44(0) 20 7947 4361

 

Britton Financial PR

Tim Blackstone

Tel: + 44 (0) 20 7242 9786

+44 (0) 7957 140416

 

 

About Plethora:

 

Plethora is headquartered in the UK and is listed on the London Stock Exchange (AIM: PLE.L). Further information is available at www.plethorasolutions.co.uk 

 

Plethora is focussed on seeking to launchPSD502 for the treatment of premature ejaculation.

 

About PSD502 & Premature Ejaculation:

PSD502 is a topical spray for the treatment of premature ejaculation containing lidocaine and prilocaine in a eutectic-like mixture. The Company anticipates launch in 2014.

 

Premature ejaculation is possibly the most common form of sexual dysfunction in men. Epidemiological studies conducted in the US and in Europe indicate a prevalence of 20 - 30% in men of all ages. There is currently no globally approved and effective pharmaceutical treatment for this condition.

 

In the absence of any widely approved pharmaceutical therapy with good patient acceptance, the premature ejaculation market offers significant potential for development and growth. An effective drug therapy for premature ejaculation may have a comparable commercial potential to the erectile dysfunction drugs.

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAFEEFISFDSEDE
Date   Source Headline
17th Nov 20107:00 amRNSChange of Adviser
10th Nov 20102:27 pmRNSHolding in Company
7th Sep 20107:00 amRNSHalf Yearly Report
29th Jul 20102:27 pmRNSHolding(s) in Company
23rd Jul 201010:55 amRNSHolding(s) in Company
19th Jul 20107:00 amRNSNew Product Launch
13th Jul 20107:00 amRNSPre-close Trading Update
30th Jun 20107:00 amRNSTerm Loan Agreement
10th Jun 201012:06 pmRNSLTIP Awards
2nd Jun 20107:00 amRNSAmerican Urological Association Showcase
27th May 20109:27 amRNSResult of AGM
17th May 20107:00 amRNSCommercial Update - The Urology Company
6th May 20107:00 amRNSAnnual Report and Accounts
5th May 20107:00 amRNSIssue of Equity
12th Apr 20107:00 amRNSExclusive Distribution Agreement
9th Mar 20107:00 amRNSPreliminary Results
24th Feb 20103:31 pmRNSHolding(s) in Company
23rd Feb 20107:00 amRNSNotice of Results
19th Jan 20107:00 amRNSPre-Close Trading Update
14th Dec 20095:23 pmRNSHolding(s) in Company
7th Dec 200911:23 amRNSResult of EGM
30th Nov 20097:00 amRNSExclusive License and Distribution Agreement
23rd Nov 20097:00 amRNSExclusive License and Distribution Agreement
19th Nov 20094:23 pmRNSDirector/PDMR Shareholding
18th Nov 20097:23 amRNSPlacing and Convertible Loan Note
30th Sep 20097:00 amRNSClinical Update re: PSD506
17th Sep 20097:00 amRNSInterim Results
7th Aug 20094:42 pmRNSHolding(s) in Company
5th Aug 200910:42 amRNSHolding(s) in Company
29th Jul 20097:00 amRNSFinal Phase III Pivotal Trial Results PSD502
16th Jul 20097:00 amRNSPSD503 Update - Evaluation and Option Agreement
25th Jun 20091:57 pmRNSAGM Statement and Trading Update
15th Jun 20093:57 pmRNSHolding(s) in Company
29th May 20093:34 pmRNSAnnual Report and Accounts and AGM Notice
26th May 20097:05 amRNSDirectorate Change
26th May 20097:00 amRNSGlobal Agreement, Restructuring and Final Results
1st Apr 20097:00 amRNSUpdate re: PSD502
19th Feb 20097:00 amRNSDirectorate Change
18th Feb 20099:24 amRNSClinical Update PSD502
16th Feb 200911:31 amRNSLoan Agreement and US License Amendment
16th Feb 200911:26 amRNSResult of General Meeting
22nd Jan 20097:00 amRNSFunding Update and Notice of GM
23rd Dec 20084:17 pmRNSHolding(s) in Company
18th Dec 200811:55 amRNSHolding(s) in Company
11th Dec 20089:12 amRNSHolding(s) in Company
8th Dec 20087:00 amRNSIssue of Equity
8th Dec 20087:00 amRNSClinical Update: PSD502
14th Nov 20087:00 amRNSHolding(s) in Company
14th Nov 20087:00 amRNSErecAid Study Results
7th Nov 20087:00 amRNSPhase III European Clinical Trial Results PSD502

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.